Purpose of Review

This review aims to provide relevant, aggregate information about a variety of disinfectants and antiseptics, along with potential utility and limitations. While not exhaustive, this review’s goal is to add to the body of literature available on this topic and give interventional providers and practitioners an additional resource to consider when performing procedures.

Recent Findings

In the current SARS-CoV2 epidemiological environment, infection control and costs associated with healthcare-associated infections (HAIs) are of paramount importance. Even before the onset of SARS-CoV2, HAIs affected nearly 2million patients a year in the USA and resulted in nearly 90,000 deaths, all of which resulted in a cost to hospitals ranging from US$28 billion to 45 billion. The onset SARS-CoV2, though not spread by an airborne route, has heightened infection control protocols in hospitals and, as such, cast a renewed focus on disinfectants and their utility across different settings and organisms.

Summary

The aim of this review is to provide a comprehensive overview of disinfectants used in the inpatient setting.

中文翻译：

---

介入治疗中的消毒剂

 审查目的

本综述旨在提供有关各种消毒剂和防腐剂的相关综合信息，以及潜在的效用和局限性。虽然并不详尽，但本次综述的目标是增加有关该主题的现有文献，并为介入提供者和从业者提供在执行手术时需要考虑的额外资源。

 最近的发现

在当前 SARS-CoV2 流行病学环境中，感染控制和与医疗保健相关感染 (HAI) 相关的成本至关重要。甚至在 SARS-CoV2 爆发之前，美国每年就有近 200 万名医院感染患者受到影响，并导致近 9 万人死亡，所有这些都给医院造成了 280 亿美元至 450 亿美元的损失。 SARS-CoV2 的出现虽然不是通过空气传播，但已加强了医院的感染控制方案，因此，人们重新关注消毒剂及其在不同环境和生物体中的效用。

 概括

本次综述的目的是全面概述住院环境中使用的消毒剂。